Evidence map›Paper›PMID 32133721›Full record

ArticleEMBO reports2020

Depression: a new enzyme AT play.

Helena Caria Martins, Gerhard Schratt

Open access · bronzeAbstract readNewsComment
In one paragraph

Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Helena Caria MartinsETH Zurich - D-HEST, Systems Neuroscience, Institute for Neuroscience, Zurich, Switzerland.
Gerhard SchrattETH Zurich - D-HEST, Systems Neuroscience, Institute for Neuroscience, Zurich, Switzerland.ORCID 0000-0001-7527-2025
ETH Zurich · CH

Funding

Deutsche Forschungsgemeinschaft DI 1501/5-2Deutsche Forschungsgemeinschaft FI 2157/2-1Swiss National Science Foundation 310030E_179651Swiss National Science Foundation 32NE30_189486
6 · The paper itself

Abstract

Neuronal activity is the main contributor to the high-energy demand of the human brain. ATP is needed for the maintenance of ionic gradients, neurotransmitter transport, and release, as well as the signaling pathways that follow activation of post-synaptic receptors. The inability to maintain a high supply of ATP through tight regulatory mechanisms can, therefore, have severe consequences for brain function. In this issue of EMBO Reports, Cui et al [1] show that pharmacological inhibition or genetic inactivation of CD39, an ectonucleotide tri(di)phosphohydrolase responsible for converting ATP into AMP, has antidepressant-like effects by maintaining high extracellular ATP levels in the presence of stress.

Indexed as

Adenosine TriphosphateDepressionAnimalsHippocampusHumansMiceNeuronsSynaptic TransmissionAdenosine Triphosphate

Identifiers

PMID32133721
PMCPMC7132210
OpenAlexW3009910211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.